Cubist Pharmaceuticals Inc: (NASD: CBST)
$54.60
-1.43 (-2.55%)
Volume 292,980
May 24 11:03 AM ET
Zacks Rank: 2-Buy 
| #2 |
Overview Quote
Stock Activity
| Day Low - High | 54.16 - 55.11 |
| 52wk Low - High | 36.73 - 56.54 |
| Previous Close | 56.03 |
| Avg. Volume | 1,095,412 |
| Industry | MED-DRUGS |
| Market Cap | 3.64 B |
| Div - Yield | 0.00 - 0.00 |
| Beta | 0.54 |
| PE (Forward) | 29.17 |
| Current Year Est. | 1.92 |
| Quarterly Earnings ESP |
7.69% |
Premium research
Zacks Rank
|
2 |
Zacks Recommendation
|
Neutral |
Zacks Industry Rank
|
110 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| PE (Forward) | 29.17 |
| PEG Ratio | 1.13 |
| Current Year Est. | 1.92 |
| Current Quarter Estimate | 0.52 |
| Most Accurate Estimate | 0.56 |
| Earnings ESP |
7.69% |
| Next Earnings Report Date | 07-18-2013 |
| EPS Last Year | 2.08 |
| Expected Earnings Growth | 25.80% |
Company Description
Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. In the U.S., Cubist markets CUBICIN, the first antibiotic in a new class of antiinfectives called lipopeptides. The Cubist product pipeline includes our lipopeptide program and our natural products screening program. Cubist is headquartered in Lexington, MA.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (06/2013) |
Next Qtr (09/2013) |
Current Year (12/2013) |
Next Year (12/2014) |
|
|---|---|---|---|---|
| Average Estimate | 0.52 | 0.52 | 1.92 | 2.52 |
| Number of Estimates | 13 | 13 | 13 | 13 |
| Low Estimate | 0.28 | 0.32 | 1.18 | 1.47 |
| High Estimate | 0.73 | 0.73 | 2.61 | NA |
| Year Ago EPS | 0.58 | 0.68 | 2.65 | 1.92 |
| EPS Growth | -9.95% | -23.76% | -27.52% | 31.24% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| CUBIST PHARM | CBST | 56.03 | |
|
| JAZZ PHARMACEUT | JAZZ | 63.00 | |
|
| SALIX PHARM-LTD | SLXP | 59.69 | |
|
| SANTARUS INC | SNTS | 22.93 | |
|
| USANA HLTH SCI | USNA | 68.51 | |
|
| CATALYST PHARMA | CPRX | 0.84 | |
|
| CELL THERAPEUT | CTIC | 1.22 | |
|
| ELAN CP PLC ADR | ELN | 12.36 | |
|
| INFINITY PHARMA | INFI | 24.36 | |
|
| LANNETT INC | LCI | 12.65 | |
|
Sector:Medical>> Industry:MED-DRUGS
COMPARE TICKER vs. Its Peers
Zacks Commentary
Priority FDA Review for Celgene's Abraxane
May 24, 2013
NPS Pharma Prices Offering
May 23, 2013
Pipeline Progress at Gilead
May 16, 2013
Cempra/Toyama Ink Deal
May 15, 2013
Synergy Pharma Posts Wider Loss
May 15, 2013
Wider-Than-Expected Loss at Athersys
May 15, 2013
Celgene Attains 52-Week High
May 14, 2013
NPS Pharma Incurs Narrower 1Q Loss
May 14, 2013
Financials
| EPS TTM | 2.08 |
| Sales | 926 |
| Net Income | 127 |
| Price/Earnings | 26.94 |
| Price/Book | 3.58 |
| Price/Cash Flow | 13.19 |
| Price/Sales | 3.85 |
News
Benzinga`s Top Downgrades - Benzinga
May 24, 2013
Cubist Pharmaceuticals Makes a Move: Down 2.3% - Financial News Network Online - Market Movers
May 24, 2013
Downgrade Alert for Cubist Pharmaceuticals (CBST) - Comtex Smartrend(R)
May 24, 2013
NPS Pharma Prices Offering - Zacks.Com
May 24, 2013
Top 4 Mid-Cap Stocks In The Drug Manufacturers-Other Industry With The Lowest PEG Ratio - Benzinga
May 24, 2013
Cubist Pharmaceuticals Up 25.2% Since SmarTrend Uptrend Call (CBST) - Comtex Smartrend(R)
May 23, 2013
Cubist to Present at Jefferies 2013 Global Healthcare Conference - Businesswire
May 23, 2013
Do These Tuesday Upgrades Present a Buying Opportunity? - TheMotleyFool
May 23, 2013
Broker Recommendations
| Current ABR | 1.97 |
| ABR (Last Week) | 2.08 |
| # of recs in ABR | 18 |
| Average Target Price | 54.86 |
| Industry Rank by ABR | 110 out of 265 |
| Rank in Industry | 5 out of 93 |
